STOK · XBRL financial data

Stoke Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (STOK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	12,405	8,780	36,555	184,420
Research and development	32,197	54,168	77,837	82,231	89,133	137,922
Selling, general and administrative	—	—	—	—	48,794	67,088
General and administrative	20,847	31,897	38,924	41,322	48,794	—
Total operating expenses	53,044	86,065	116,761	123,553	137,927	205,010
Operating income (loss)	(53,044)	(86,065)	(104,356)	(114,773)	(101,372)	(20,590)
Interest income	744	—	—	9,957	12,664	13,765
Interest expense	—	—	—	49	26	9
Other income (expense)	57	140	167	166	(247)	(51)
Income tax expense (benefit)	—	—	—	—	—	0
Net income (loss)	(52,243)	(85,805)	(101,067)	(104,699)	(88,981)	(6,885)
Earnings per share, basic USD per share	—	(2.34)	(2.60)	(2.38)	(1.65)	(0.12)
Earnings per share, diluted USD per share	—	(2.34)	(2.60)	(2.38)	(1.65)	(0.12)
Weighted average shares, basic thousands of shares	—	36,739	38,897	43,995	54,009	59,219
Weighted average shares, diluted thousands of shares	—	36,739	38,897	43,995	54,009	59,219

Fiscal years (STOK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	287,308	144,895	113,556	191,442	127,983	84,220
Marketable securities	0	74,915	116,039	9,952	88,916	200,450
Marketable securities, non-current	—	—	—	—	29,824	106,260
Accounts receivable	—	—	—	—	1,668	5,936
Prepaid and other current assets	6,435	9,159	—	—	—	—
Total current assets	293,930	229,218	244,070	215,339	232,756	305,700
Property and equipment, net	2,675	4,139	6,675	5,823	3,909	3,146
Right-of-use asset	1,115	4,939	4,753	6,611	4,345	3,101
Total assets	297,925	238,865	256,067	228,342	271,555	418,434
Accounts payable	1,495	2,385	766	1,695	2,498	4,939
Total current liabilities	11,425	17,139	31,394	30,819	40,056	57,875
Lease liability, non-current	80	3,532	2,717	4,773	2,452	1,141
Total liabilities	11,847	21,088	71,218	68,777	42,534	65,977
Accumulated deficit	(110,278)	(196,083)	(297,150)	(401,849)	(490,830)	(497,715)
Total stockholders' equity	286,078	217,777	184,849	159,565	229,021	352,457
Total liabilities and equity	297,925	238,865	256,067	228,342	271,555	418,434
Common shares outstanding (cover page) thousands of shares	36,664	37,359	44,148	46,304	54,078	59,151

Fiscal years (STOK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(52,243)	(85,805)	(101,067)	(104,699)	(88,981)	(6,885)
Stock-based compensation	5,768	16,450	22,854	25,257	27,470	32,238
Net cash from operating activities	(42,221)	(66,907)	(31,866)	(81,067)	(86,851)	45,585
Purchases of property and equipment	1,050	1,200	3,962	1,616	203	670
Net cash from investing activities	(1,050)	(76,426)	(45,882)	105,946	(107,475)	(186,812)
Net cash from financing activities	108,108	1,284	46,409	53,007	131,094	97,389
Net change in cash	64,837	(142,049)	(31,339)	77,886	(63,232)	(43,838)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Stoke Therapeutics	107,271	11,255	(62,686)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
Trevi Therapeutics	54,302	not reported	(17,429)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Mersana Therapeutics	56,391	11,009	(3,192)*	5.0M	17.7 quarters	Q3 FY25 10-QSep 30, 2025
Evolus	41,700	77,952	(1,933)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Xencor	59,622	116,520	2,642*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Amphastar Pharmaceuticals	223,614	183,903	51,324*	42.5M	—	Q2 FY26 10-QJun 30, 2026
Anaptysbio	133,826	27,488*	(26,640)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Merus	367,491	12,150	(84,917)*	75.8M	7.5 quarters	Q3 FY25 10-QSep 30, 2025
Savara	41,800	not reported	(29,747)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.